Irinotecan in Treating Patients With Esophageal or Stomach Cancer

Part of paid clinical trials in Bakersfield, California.

Sponsor
Jonsson Comprehensive Cancer Center
Study ID
NCT00003748
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • irinotecan hydrochloride — DRUG
    One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have esophageal or stomach cancer.

Key Dates

Start date
Aug 31, 1998
Status verified
Jul 2012
Primary completion
Jun 30, 2000
Completion
Jan 31, 2005

Study Design

Enrollment
40 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: irinotecan hydrochloride
    One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.

Primary Outcome Measure

To determine the antitumor activity of irinotecan hydrochloride (CPT-11) in patients with unresectable adenocarcinoma of the esophagus and gastric cardia who have failed prior chemotherapy [ Time Frame: 2 years ]

Locations (25)

FacilityCityStateZIPSite coordinators
Comprehensive Blood and Cancer CenterBakersfieldCalifornia93309-
St Jude Heritage Health FoundationFullertonCalifornia92835-
Daniel Freeman Memorial HospitalInglewoodCalifornia90301-
UCLA - Antelope Valley Cancer CenterLancasterCalifornia93534-
Pacific Shores Medical GroupLong BeachCalifornia90813-
Jonsson Comprehensive Cancer Center, UCLALos AngelesCalifornia90095-1781-
Community Hospital of the Monterey PeninsulaMontereyCalifornia93940-
Office of Jerome L. RubinMontereyCalifornia93940-
Office of Eddie Hu, M.D.Monterey ParkCalifornia91754-
Ventura County Hematology-Oncology Medical Group, Inc.OxnardCalifornia93030-
Wilshire Oncology Medical CenterPomonaCalifornia91767-
Salinas Valley Memorial HospitalSalinasCalifornia93901-
Cancer Center of Santa BarbaraSanta BarbaraCalifornia93105-
Sansum Medical ClinicSanta BarbaraCalifornia93105-
James L. Poth, M.D., Michael Alexander, M.D., Inc.Santa CruzCalifornia95065-
Marian Medical CenterSanta MariaCalifornia93454-
Office of Marilou TerpenningSanta MonicaCalifornia90404-
Office of Robert C. KleinSanta MonicaCalifornia90404-
Dominican and Watsonville Community HospitalSoquelCalifornia95073-
Los Robles Regional Medical CenterThousand OaksCalifornia91360-
Cancer Care Associates Medical GroupTorranceCalifornia90505-
UCLA Cancer Center - Santa ClaritaValenciaCalifornia91355-
Oncology Medical Center of North CountyVistaCalifornia92083-
Valley Hematology and OncologyWest HillsCalifornia91307-
Cancer Care ConsultantsLas VegasNevada89119-

Find similar trials in Bakersfield, CA

By condition
Esophageal cancerGastric cancer
By specialty
OncologyGI oncology
By research site
Comprehensive Blood and Cancer Center· Bakersfield, CASt Jude Heritage Health Foundation· Fullerton, CADaniel Freeman Memorial Hospital· Inglewood, CAUCLA - Antelope Valley Cancer Center· Lancaster, CAPacific Shores Medical Group· Long Beach, CAJonsson Comprehensive Cancer Center, UCLA· Los Angeles, CA

Related Studies